Live Breaking News & Updates on Bharat Biotech Nasal Vaccine|Page 5

Bharat Biotech seeks DCGI nod to conduct trials of nasal Covid-19 vaccine
Bharat Biotech chairman Krishna Ella says this nasal vaccine will revolutionise Indian vaccine making capabilities and help it leapfrog along with Europe, the US and China
BusinessToday.In | January 9, 2021 | Updated 00:19 IST
There are no intra-nasal COVID-19 vaccines under trial in India at the moment
Homegrown pharma major Bharat Biotech has sought Drug Controller General India s (DCGI) approval to conduct nasal Covid-19 vaccine trials in India. The company had received emergency approval for its Covid-19 vaccine, Covaxin, on January 3, though it is still conducting phase-3 trials in India.
There are no intra-nasal COVID-19 vaccines under trial in India at the moment. The company has developed a new single-dose nasal COVID-19 vaccine in a partnership with Washington University in St Louis, USA, which is touted to be super efficient and a game-changer. ....

United States , Andhra Pradesh , Krishna Ella , Washington University In St Louis , Serum Institute Of India , Bharat Biotech , Drug Controller General India , Washington University , Managing Director , Serum Institute , Nasal Vaccine , Bharat Biotech Nasal Vaccine , Coronavirus Vaccine Update , Coronavirus Vaccine , Coronavirus Vaccine Trial , Coronavirus Vaccine Trial In India , Oxford Astrazeneca Vaccine , Astra Zeneca Vaccine Trial , Oxford Vaccine Trial In India , ஒன்றுபட்டது மாநிலங்களில் , ஆந்திரா பிரதேஷ் , கிருஷ்ணா எல்லா , வாஷிங்டன் பல்கலைக்கழகம் இல் ஸ்டம்ப் லூயிஸ் , சீரம் நிறுவனம் ஆஃப் இந்தியா , பாரத் பயோடெக் , மருந்து கட்டுப்படுத்தி ஜநரல் இந்தியா ,